Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 32 resultados

SciLifeLab PULSE: SciLifeLab Programme for fUture Leaders in life SciencE SciLifeLab PULSE is a MSCA-COFUND postdoctoral programme of excellence in Life Sciences coordinated by the Swedish research infrastructure S...
2024-09-16 - 2030-08-31 | Financiado

HAIF: Human Centric Artificial Intelligence for Sustainable Future For the EU to strengthen its role as the global leader in trustworthy AI, experts on ethical, human-centric and sustainable use of AI are ur...
2024-09-13 - 2029-12-31 | Financiado

NOVEL: Novel brain health solutions across four focus areas Prevention and care Methods and data Innovat... The NOVEL Postdoctoral Programme pioneers in merging diverse socio-cultural and scientific expertise to forge new brain health solutions, en...
2024-08-05 - 2029-11-30 | Financiado

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado

TransPharm: Transforming into a sustainable European pharmaceutical sector ORION OYJ participó en un HORIZON EUROPE: HORIZON-HLTH-2021-IND-07 TransPharm two-track approach focusses on the one hand on the compounds itself by identifying greener and more sustainable-by-design Active...
2022-05-19 - 2026-05-31 | Financiado

IDEA-FAST: Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegene... ORION OYJ participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-...
2019-12-18 - 2026-04-30 | Financiado

PIONEER: Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope ORION OYJ participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such...
2018-06-14 - 2023-10-31 | Financiado

EQIPD: European Quality In Preclinical Data ORION OYJ participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Pharmaceutical industry, as well as basic science, depend on robust data and scientific rigor as key drivers for decision making, patent str...
2017-08-18 - 2021-09-30 | Financiado

TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicine... ORION OYJ participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new me...
2016-12-22 - 2022-08-31 | Financiado

PHAGO: Inflammation and AD modulating microglia function focussing on TREM2 and CD33 Sofia ref. 115976 ORION OYJ participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaqu...
2016-12-16 - 2022-04-30 | Financiado

TreatER: Clinical study in Parkinson s disease with two unique goals 1 Proof of concept of CDNF protein for... ORION OYJ participó en un H2020: H2020-SC1-2016-2017 The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of int...
2016-12-09 - 2020-12-31 | Financiado

CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... ORION OYJ participó en un FP6: Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
2015-01-01 - 2019-12-31 | Financiado

ORBITO: Oral biopharmaceutics tools ORION OYJ participó en un FP6: The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug de...
2012-10-01 - 2018-09-30 | Financiado

CHEM21: Chemical Manufacturing Methods for the 21st Century Pharmaceutical Industries ORION OYJ participó en un FP6: CHEM21 is a project that will develop a broad based portfolio of sustainable technologies for green chemical intermediate manufacture aimed...
2012-10-01 - 2017-06-30 | Financiado

STEMBANCC: Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) ORION OYJ participó en un FP6: StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug disc...
2012-10-01 - 2018-03-31 | Financiado

MIP-DILI: Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury ORION OYJ participó en un FP6: The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will addres...
2012-02-01 - 2017-03-31 | Financiado

SAFESCIMET: European Modular Education and Training Programme in Safety Sciences for Medicines ORION OYJ participó en un FP6: Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has...
2010-01-01 - 2016-09-30 | Financiado

EMTRAIN: European Medicines Research Training Network ORION OYJ participó en un FP6: EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will es...
2009-10-01 - 2016-09-30 | Financiado

EU2P: European programme in Pharmacovigilance and Pharmacoepidemiology ORION OYJ participó en un FP6: The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia...
2009-09-01 - 2016-06-30 | Financiado

NEWMEDS: Novel Methods leading to New Medications in Depression and Schizophrenia ORION OYJ participó en un FP6: Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are...
2009-09-01 - 2015-02-28 | Financiado

ORION CORPORATION